Dermapharm Holding SE (DMP) — Working Capital to Net Assets Ratio
Dermapharm Holding SE (DMP) has a Working Capital to Net Assets ratio of 53.0% as of March 2026. Working capital of €389.81 Million (current assets of €780.05 Million minus current liabilities of €390.24 Million) is measured against net assets of €735.17 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. See operational self-sufficiency of Dermapharm Holding SE to measure how many days the company can operate on defensive assets alone.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Dermapharm Holding SE Working Capital to Net Assets (2013–2025)
This chart shows how Dermapharm Holding SE's Working Capital to Net Assets ratio has evolved across 13 annual periods from 2013 to 2025. As of March 2026, the ratio stands at 53.0%, reflecting working capital of €389.81 Million against net assets of €735.17 Million EUR. For the complete balance sheet picture, see balance sheet size of Dermapharm Holding SE.
Annual Working Capital to Net Assets for Dermapharm Holding SE (2013–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Dermapharm Holding SE from 2013 to 2025, covering 13 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. Check DMP financial resilience to evaluate the company's liquid asset resilience ratio.
| Year | WC/NA Ratio | Working Capital (EUR) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 51.3% | €360.00 Million | €701.83 Million | €702.92 Million | €342.93 Million | ▲ +7.5 pp |
| 2024 | 43.8% | €266.58 Million | €608.29 Million | €593.50 Million | €326.92 Million | ▲ +0.5 pp |
| 2023 | 43.3% | €236.01 Million | €545.05 Million | €630.50 Million | €394.49 Million | ▼ -16.1 pp |
| 2022 | 59.4% | €316.15 Million | €532.49 Million | €533.95 Million | €217.79 Million | ▼ -13.4 pp |
| 2021 | 72.7% | €363.61 Million | €499.83 Million | €519.22 Million | €155.61 Million | ▼ -9.6 pp |
| 2020 | 82.3% | €267.18 Million | €324.58 Million | €400.05 Million | €132.87 Million | ▼ -5.7 pp |
| 2019 | 88.1% | €250.52 Million | €284.49 Million | €352.94 Million | €102.42 Million | ▲ +0.3 pp |
| 2018 | 87.8% | €224.84 Million | €256.08 Million | €371.24 Million | €146.40 Million | ▼ -64.6 pp |
| 2017 | 152.4% | €112.29 Million | €73.69 Million | €192.87 Million | €80.58 Million | ▲ +84.1 pp |
| 2016 | 68.3% | €41.54 Million | €60.81 Million | €156.96 Million | €115.42 Million | ▼ -112.9 pp |
| 2015 | 181.2% | €80.53 Million | €44.44 Million | €142.10 Million | €61.57 Million | ▼ -29.0 pp |
| 2014 | 210.2% | €71.50 Million | €34.01 Million | €168.54 Million | €97.04 Million | ▲ +178.2 pp |
| 2013 | 32.0% | €13.24 Million | €41.36 Million | €181.90 Million | €168.66 Million | — |